Drugs / LY3053102
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01736241 | Dec 2012 → Jul 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02020616 | Dec 2013 → Feb 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3053102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02020616 ↗ |
| Route | Subcutaneous | “was subcutaneously administered” NCT01736241 ↗ |